NCT07050472Completed
Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)
Durvalumab as Consolidation Therapy After Concurrent Chemoradiotherapy (cCRT) for Patients With Limited-stage Small-cell Lung Cancer (LS-SCLC): A Retrospective, Single-center, Real-world Cohort Study
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 45 (actual)
- First submitted
- 12 Jun 2025
- Start date
- 11 Aug 2025
- Primary completion date
- 12 Aug 2025
- Lead sponsor
- Anhui Shi, MD
- Diseases
- Lung cancer
- NCT number
- NCT07050472
What you commit to
- Study type: Observational
- Participants enrolled: 45
- From 11 Aug 2025 to the primary completion date, 12 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participated in other interventional clinical trial for the treatment of any cancer during durvalumab therapy.
Other
- Mixed SCLC and NSCLC histology.
Who the study is looking for
- Aged ≥18 at initial diagnosis.
- Histologically or cytologically documented limited-stage SCLC (Stage I-III SCLC \[T any, N any, M0\] according to the American Joint Committee on Cancer Staging Manual \[AJCC Cancer Staging Manual, 9th Edition\] or the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology \[IASLC Staging Manual in Thoracic Oncology 2016\]).
- Received concurrent chemoradiotherapy (cCRT) as first-line treatment and consolidative durvalumab prior to disease progression or death:
- Received 4 cycles of platinum-based chemotherapy concurrent with radiotherapy.
- The chemotherapy regimen must contain carboplatin/cisplatin and etoposide.
- Received a total dose of radiation of 60 to 66 Gy over 6 weeks for standard QD radiation schedules, 45 Gy over 3 weeks or a simultaneous integrated boost of 54 Gy over 3 weeks for hyperfractionated BID radiation schedules.
- Radiotherapy must have commenced no later than the end of Cycle 2 of chemotherapy.
- Received at least 1 dose of durvalumab. The first dose of durvalumab received between 1 Jan 2020 and 31 Dec 2023 at Peking University Cancer Hospital.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Cancer Hospital and Institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.